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Abstract
Objective—Compare incidence of opioid-managed pelvic pain within 12-months after 
hysteroscopic and laparoscopic sterilization.
Methods—Using administrative claims, we identified women age 18-49 without recent history 
of childbirth who underwent hysteroscopic or laparoscopic sterilization between 2005-2012. We 
defined the outcome as ≥2 diagnoses for pelvic pain and ≥2 prescription fills for opioids. We 
calculated adjusted hazard ratios (HR) using Cox models and propensity score methods (matching 
and inverse-probability-of-treatment-weighting [IPTW]).
Results—We identified 71,875 eligible women (hysteroscopic n=26,927 [37.5%], laparoscopic 
n=44,948 [62.5%]). Of those, 236 (0.88%) hysteroscopic patients and 420 (0.93%) laparoscopic 
patients experienced the outcome (crude HR=0.97, [95%CI: 0.83, 1.14]). Adjusted analyses also 
yielded near-null results (matched HR=1.08 [95%CI: 0.90, 1.31]; IPTW HR=0.97 [95%CI: 0.80, 
1.18]). While most sensitivity analyses generated results close to the null, hazard ratios estimated 
using propensity score matching ranged from 0.65 to 1.53.
Conclusions—Among women without recent history of childbirth, we did not find compelling 
evidence of a clinically meaningful increase in the incidence of pelvic pain requiring opioids 
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during the year after hysteroscopic sterilization. However, effects observed in sensitivity analyses 
may merit further investigation.
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INTRODUCTION
Hysteroscopic sterilization is a relatively new alternative to laparoscopic sterilization, in 
which implanted coils prompt permanent occlusion of the fallopian tubes. Unlike 
laparoscopic sterilization, hysteroscopic sterilization requires no surgical incisions and is 
frequently completed in the outpatient setting. Media reports have described instances of 
prolonged abdominal/pelvic pain in women who underwent hysteroscopic sterilizations, 
prompting Bayer to add chronic pelvic pain as a long-term risk in the brochure for their 
hysteroscopic sterilization device, Essure® (Bayer, Morrisville, NC).1,2 However, 
documented cases in the medical literature of chronic pelvic pain after hysteroscopic 
sterilization are rare.3,4
The hysteroscopic sterilization device contains an inner coil of stainless steel with 
polyethylene terephthalate (PET) fibers and an outer coil of titanium-nickel (nitinol).5 The 
coil is placed into the interstitial portion of each fallopian tube under hysteroscopic 
guidance. Polyethylene fibers have long been used with success in other medical devices 
requiring tissue ingrowth such as arterial grafts.6 Similar tissue response in the fallopian 
tubes ultimately results in tubal occlusion. Nickel allergy, chronic inflammation, and coil 
perforation or malposition are postulated mechanisms by which hysteroscopic sterilization 
could cause chronic abdominopelvic pain.3,4,7
Few studies have evaluated the risk of rare but serious adverse events after hysteroscopic 
sterilization.4,8-10 Due to the large sample size needed, randomized controlled trials are 
unable to address rare pain events after hysteroscopic sterilization. The two studies that 
actively compare pain events between laparoscopic and hysteroscopic sterilization patients 
were both prospective cohort studies with fewer than 100 patients, insufficiently powered to 
evaluate rare outcomes.9,10 Furthermore, neither evaluated outcomes beyond 90 days after 
sterilization. On October 18, 2013 the FDA responded to patient advocacy groups with a 
review stating that the currently limited evidence base does not link hysteroscopic 
sterilization to above-normal rates of pain or discomfort.11
Given the limited data available, there is a need for large-sample, population-based research 
evaluating pain outcomes after hysteroscopic sterilization. To address this evidence gap, we 
compared incidence of opioid-managed pelvic pain within 12 months in hysteroscopic and 
laparoscopic sterilization patients using data from a large healthcare claims database.
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METHODS
Data Source
We used Truven Health's MarketScan Commercial Claims & Encounters Database 
(Copyright © 2013 Truven Health Analytics Inc.; all rights reserved) for the years 
2005-2012, which contains de-identified healthcare and pharmaceutical claims for enrollees 
in over 150 large employer-provided insurance plans from across the United States. In the 
most recent year of data, it covered over 50 million lives.12 Approximately 55% of the U.S. 
population (170.1 million people) had employment-based insurance in 2011.13 These data, 
therefore, constitute a substantial portion of the U.S. population with employer-provided 
insurance.
Study Population
We identified a cohort of women ages 18-49 from inpatient and outpatient medical claims 
from 2005-2012 with current procedural terminology (CPT) codes for either hysteroscopic 
(CPT: 58565) or laparoscopic (CPT: 58670, 58671) sterilization. We did not include 
postpartum sterilizations since 1) we considered women with recent deliveries to be 
clinically unique and 2) we were concerned postnatal payment bundling may limit our 
ability to study these patients using claims data.
Though approved in 2002, hysteroscopic sterilization procedures cannot be reliably 
identified using administrative claims data until 2005 when unique codes for hysteroscopic 
sterilization were added to the Physician Fee Schedule.14 Two hysteroscopic sterilization 
devices were marketed during the study period: Essure® (Bayer, Morrisville, NC) from 
2005 to 2012 and Adiana® (Hologic, Bedford, MA) from 2009 to 2012. The CPT codes for 
hysteroscopic sterilization do not identify which device was placed.
In order to create a uniform time window to ascertain baseline covariate information 
(henceforth look-back), we restricted the cohort to women with six months of continuous 
enrollment before sterilization. We only included the first eligible procedure undergone by 
each woman and excluded women with claims for both sterilization procedures on the same 
day. Women were excluded if they had a claim for endometrial ablation on the same day or 
if their six-month history contained a claim related to childbirth, any diagnosis used in the 
outcome definition, or any prescription fill for opioids. For codes used to define study 
exclusions, see Web appendix 1. We assumed opioid prescriptions within 14 days of 
sterilization were routine medications directly related to the index procedure and did not use 
them to determine study eligibility or outcomes.
Outcomes
Starting follow up 14 days after sterilization, we evaluated opioid-managed pelvic pain 
using pharmaceutical claims and International Classification of Diseases, Ninth Revision 
(ICD-9) diagnosis codes associated with service claims. To qualify for the outcome, we 
required patients 1) have at least two diagnoses relating to pelvic pain, including 
dysmenorrhea (ICD-9: 625.3), abdominal pain (789.0x), or symptoms associated with 
female genital organs (ICD-9: 625.8 and 625.9) occurring on separate days during follow-
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up, and 2) have at least two opioid prescriptions filled on separate days. Though the codes 
used in the outcome which refer to symptoms associated with female genital organs (ICD-9: 
625.8, 625.9) may include non-pain symptoms, physicians frequently use them to code 
pelvic pain and prior research efforts (including the Agency for Health Research and Quality 
Clinical Classification Software) have used them accordingly.15-17 We recorded the 
outcome date for each patient as the earliest date by which all outcome criteria were 
satisfied. Observations were censored when patients disenrolled (e.g. switched to an 
insurance plan not captured by MarketScan) or at the end of study follow-up (one year after 
sterilization).
Covariates
Covariates of interest included age at the time of sterilization, region-of-service and calendar 
year. We evaluated healthcare utilization variables in the six-month history, including any 
hospital admission and prior surgeries (identified using CPT codes for surgical anesthesia) 
and continuous variables for the number of prescription fills and outpatient visits. We used 
CPT and ICD-9 codes to identify relevant procedures (e.g., non-obstetric ultrasounds) and 
prevalent conditions (e.g., diabetes) in the patient's history. We considered all procedures 
and diagnoses present in >1% of either sterilization group, in addition to some less prevalent 
procedures and diagnoses which were of special clinical interest. For codes used to define 
study covariates, see Web Appendix 1.
Statistical Analyses
We compared baseline characteristics of laparoscopic and hysteroscopic sterilization 
patients and evaluated covariate imbalance between the sterilization groups for both 
categorical and continuous covariates using the standardized difference.18
We estimated the probability of each patient receiving hysteroscopic sterilization conditional 
on baseline covariates (also called the propensity score) using logistic regression.19 
Covariate distributions shifted over calendar time (e.g. hysteroscopic patients were more 
likely than laparoscopic patients to have pelvic organ prolapse, fibroids, and a history of 
inpatient hospital stay early in the study period, but were less likely to have them later in the 
study period). To account for changes in the channeling of patients to (or away from) this 
relatively novel procedure over the study period, propensity scores were estimated using 
calendar-year specific models.
We included covariates in propensity score models based on the plausibility and the 
magnitude of their association with opioid-managed pelvic pain. To evaluate the magnitude 
of covariate-outcome relationships, we used Cox proportional hazard models within 
treatment groups. Final propensity score models included age, obesity, diabetes, excessive/
frequent menstruation, polycystic ovary syndrome (PCOS), chronic obstructive pulmonary 
disease (COPD), any inpatient admission, prior surgery, as well as the number of outpatient 
visits and the number of distinct prescriptions in the patient's six-month history.
We used two propensity score adjustment methods: 1) propensity score matching and 2) 
stabilized inverse-probability-of-treatment-weighting (IPTW).20 Both propensity score 
matching and IPTW methods control confounding by balancing the distribution of measured 
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covariates across treatment groups. We formed propensity score matched pairs within 
calendar years using a 1-to-1 greedy matching algorithm with a maximum caliper of 0.1.21
We compared the baseline characteristics of the matched and weighted cohorts by 
sterilization type to ensure balance of measured covariates of interest. Cox proportional 
hazards regression models were used to estimate adjusted hazard ratios and 95% confidence 
intervals for the effect of sterilization type on opioid-managed pelvic pain, accounting for 
censoring. We compared the cumulative incidence of opioid-managed pelvic pain at 2, 4, 6, 
8, 10, and 12 months post-sterilization between treatment groups for the crude, IPTW, and 
matched analyses using Kaplan-Meier survival curves.
We conducted seventeen sensitivity analyses, including analyses varying the outcome 
definition (SA 1-8), perioperative period (SA 9-12), and look-back (SA 14-15), which are 
described in detail in Web appendix 2. We also conducted two stratified analysis, one 
evaluating effect estimates by quartiles (defined within calendar year) of the propensity 
score and a second evaluating effect estimates within discrete windows during follow-up.
This study was reviewed by University of North Carolina's institutional review board (study 
#: 13-2445) and found to be exempt. We conducted all analyses using SAS 9.3 (SAS 
Institute, Cary, NC).
RESULTS
We identified a total of 71,875 eligible women who underwent either a laparoscopic or 
hysteroscopic sterilization procedure between 2005 and 2012 (Figure 1). Of these, 26,927 
(37.5%) were hysteroscopic sterilizations and 44,948 (62.5%) were laparoscopic. Overall, 
656 (0.91%) women experienced the outcome of opioid-managed pelvic pain including 236 
(0.88%) women in the hysteroscopic group and 420 (0.93%) women in the laparoscopic 
group. The mean (median) follow-up times were 275 (365) days among hysteroscopic 
sterilization patients and 283 (365) days among laparoscopic sterilization patients.
Table 1 describes the characteristics of laparoscopic and hysteroscopic patients in the crude, 
propensity score matched analysis, and IPTW analyses. Though the hysteroscopic cohort 
was slightly older than the laparoscopic cohort, age distributions were similar between the 
sterilization groups. Compared to laparoscopic sterilization, hysteroscopic sterilization 
patients more often had a history of excessive or frequent menstruation and less often had a 
history of ovarian cysts or absence of menstruation. The hysteroscopic sterilization group 
had greater use of non-obstetric ultrasounds and depot medroxyprogesterone acetate 
(DMPA), an injectable long-term contraceptive, before sterilization. The mean number of 
prescriptions filled during the baseline period was higher among hysteroscopic patients. The 
propensity score matched analysis was comprised of 50,986 subjects, including 25,493 
(95%) hysteroscopic sterilization patients. In matched and IPTW analyses, all modeled 
covariates (i.e. those that impacted the outcome) were balanced between the sterilization 
groups (standardized differences ≤0.01).
In the crude analysis, the one-year incidence of opioid-managed pelvic pain was 
approximately equal among hysteroscopic and laparoscopic (referent) patients (HR=0.97, 
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95%CI 0.83–1.14). The crude cumulative incidence was greater in the hysteroscopic 
sterilization patients at six months but not at one year (Figure 2A and Web appendix 3). At 
six months, the cumulative incidence was 0.48% (95%CI 0.40%–0.58%) in hysteroscopic 
patients and 0.40% (95%CI 0.34%–0.47%) in laparoscopic patients. At 12 months, it 
reached 1.22% (95%CI 1.07%–1.38%) and 1.29% (95%CI 1.17%–1.41%) in hysteroscopic 
and laparoscopic patients, respectively.
The effect estimate under the IPTW analysis was similar to the crude estimate (HR=0.97, 
95%CI 0.80–1.18), while the propensity score matched analysis (HR=1.08, 95%CI 0.90–
1.31) indicated marginally increased risk in hysteroscopic sterilization patients. In the IPTW 
analysis, the mean stabilized weight was 1.00 in both the laparoscopic and hysteroscopic 
sterilization groups.
The IPTW Kaplan-Meier analysis indicated that cumulative incidence did not differ by 
sterilization status throughout the study period. The propensity score matched cumulative 
incidence in the hysteroscopic group was slightly higher over the course of the study period, 
though this was not significantly different from the laparoscopic group (Figure 2B and Web 
appendix 3). At six months, cumulative incidence reached 0.48 (95%CI 0.39%–0.58%) in 
the hysteroscopic group and 0.38% (95%CI 0.30%–0.47%) in the laparoscopic group. At 12 
months, it reached 1.23% (95%CI 1.08%–1.41%) and 1.17% (95%CI 1.02%–1.34%) in 
hysteroscopic and laparoscopic patients, respectively.
The crude, IPTW and propensity score matched results of the sensitivity analyses are 
presented in Figure 3. Nearly all sensitivity analyses indicate no difference in the risk of 
opioid-managed pelvic pain between the sterilization groups. Two notable exceptions were 
the analysis in which we required 30 days supply of opioids in the outcome definition (SA 
4) and the sensitivity analysis in which we used up to five years of available pre-exposure 
claims history to define study covariates and exclusion criteria (SA 15). The use of the more 
specific outcome definition produced protective effects (HR=0.65, 95%CI 0.41–1.03) while 
the extended look-back period suggested an increased risk in the hysteroscopic group 
(HR=1.53, 95%CI 1.11–2.11). Combining the two analyses (SA 17) yielded results close to 
the null (HR=0.93, 95%CI 0.46–1.87).
In the stratified analysis estimating effects within quartiles of the propensity score 
distribution, the estimated hazard ratio was 0.96 (95%CI 0.71–1.29) in the first quartile, 1.21 
(95%CI 0.89–1.66) in the second quartile, 0.88 (95%CI 0.60–1.29) in the third quartile, and 
0.96 (95%CI 0.71–1.30) in the fourth quartile among 5,407, 6,486, 7,077, and 7,957 
hysteroscopic patients respectively. The results of the analysis evaluating effects within 
discrete windows during follow-up (Web appendix 4) indicate possible increased risk of 
opioid-managed pelvic pain among hysteroscopic patients in time periods more proximal to 
sterilization (not counting first 14 days) that diminishes in more distal time periods.
DISCUSSION
Among women without a recent history of childbirth, we report a non-significant 8% 
increase (HR=1.08, 95%CI 0.90–1.31, p=0.42) in the hazard of opioid-managed pelvic pain 
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over 12 months of follow-up in patients sterilized hysteroscopically versus laparoscopically. 
Given the low prevalence of the outcome, an effect of this magnitude is clinically 
inconsequential. Given that hysteroscopic sterilization represented 50% of all sterilizations 
in the most recent year of these data (2012), evaluating the relative safety of this method is 
an important public health issue.
Only two prior studies have compared pain outcomes in laparoscopic and hysteroscopic 
sterilization patients, both of which were prospective studies based on patient surveys.9,10 
The sample size in this study (26,927 hysteroscopic and 44,948 laparoscopic) is 
substantially larger those of Syed et al.10 and Duffy et al.9, which included fewer than 150 
patients combined. While both studies reported fewer pain events among hysteroscopic 
sterilization patients, neither enrolled sufficient numbers of patients to evaluate the effect of 
sterilization type on rare outcomes. One had a follow-up of four weeks10 and the other 90 
days9, which would make the present study's follow-up substantially longer than the existing 
literature. However, the present study could only evaluate an opioid-managed pain proxy 
and the two prospective studies were better able to assess pain using patient surveys.
In general, the effect estimates from the matched analysis were more likely to suggest 
greater risk for hysteroscopic patients than the results of the IPTW analysis. Dissimilarity 
between hazard ratios estimated in the propensity score matched and IPTW analyses may be 
due to the fact that they estimate different effects in the presence of treatment effect 
heterogeneity.22,23 However, sample size considerations limit our ability to fully explore 
whether there are sources of effect heterogeneity present.
One limitation of these data is that pharmaceutical claims do not include the clinical 
indication for the prescription, so we investigated whether other conditions (unrelated to the 
device) may have occurred during follow up that would account for differences in opioid 
utilization between the two groups. In comparing other pain-related diagnoses among 
women who had the event, we found that fibroid diagnoses occurred more frequently during 
follow-up among hysteroscopic patients (20%) than among laparoscopic patients (13%). 
This difference may partially explain the greater opioid use observed in the hysteroscopic 
group. In a sensitivity analysis (SA 3) requiring opioid prescriptions to occur within a week 
following pelvic pain diagnoses, we found no difference between the groups (HR=1.03, 
95%CI 0.75–1.43).
Our objective was to evaluate long-term pelvic pain rather than acute post-procedure pain. 
However, from a patient perspective, being able to compare the risk of opioid-managed 
pelvic pain any time during the year after the procedure, including the immediate post-
operative period may also be important. In a sensitivity analysis (SA 10) that counted all 
post-procedure opioid use toward the outcome we found no effect (HR=1.01, 95%CI 0.85–
1.21).
In the sensitivity analysis that allowed up to five years of history (SA 15), the results of the 
IPTW analysis (HR=1.15, 95%CI 0.87–1.52) and the matched analysis (HR=1.53, 95%CI 
1.11–2.11) were further from the null than those of the primary analysis. A recent simulation 
study reported that an all-available approach to covariate measurement led to less bias than 
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using a six-month history for all subjects.24 However, the relevance of these findings is 
uncertain when the treatment populations are changing composition over time or when the 
all-available history is used to define criteria for exclusion, both of which are the case in this 
analysis. Furthermore, while this result is potentially important, the absolute difference in 
risk is small due to the rare outcome.
This study has several limitations. First, there may be important unmeasured variables that 
result in residual confounding in the relationship between sterilization and opioid-managed 
pain outcomes (e.g. BMI). Second, opioid-managed pelvic pain is only a proxy for true pain 
outcomes and is likely limited in both sensitivity and specificity. Validated instruments 
measuring pain/discomfort exist but are impractical in studies with very large sample sizes. 
We conducted multiple sensitivity analyses to explore alternative outcome definitions, none 
of which indicated elevated risk in the hysteroscopic sterilization group. Third, in our 
primary analysis we restricted evaluation of baseline covariates and exclusions for patient 
histories with evidence of the outcome-of-interest to a six-month look-back period, which 
may result in under-ascertainment of relevant covariates and residual confounding. Fourth, 
this study only evaluated outcomes up to one year following sterilization. Fifth, by studying 
pharmaceutical claims we assume that a prescription fill implies medication use, which may 
not be the case. However, we sought to reduce this misclassification by requiring two opioid 
prescriptions for the outcome. Finally, the employer-provided insurance plan enrollees 
studied may limit generalizability since they may differ slightly from the general population 
in health status and healthcare utilization. However they are a stably insured population, 
enabling longitudinal research not possible with conventional data sources.
This study has multiple strengths. Using administrative claims data enables analysis of a 
large sample needed to evaluate rare outcomes. To our knowledge, this is the largest study to 
date evaluating adverse events after hysteroscopic sterilization. Furthermore, exposure 
ascertainment was both highly sensitive and highly specific. Finally, we conducted extensive 
sensitivity analyses to evaluate the effect of sterilization type on pain outcomes under a 
variety of assumptions and outcome definitions. With the exception of the analysis that 
included all available claims history (up to five years), none of the sensitivity analyses 
indicated increased incidence of opioid-managed pelvic pain in hysteroscopic sterilization 
patients.
Though expensive and logistically difficult to implement due to the low incidence of the 
outcome, future studies able to ascertain pain endpoints with greater sensitivity and 
specificity would be helpful in clarifying the relationship between sterilization type and 
chronic pain events. Furthermore, research is still needed which evaluates other adverse 
events unrelated to pain (e.g., bleeding outcomes) that have been reported by patients who 
have undergone recent hysteroscopic sterilization.
Through the use of administrative claims data, we were able to evaluate the incidence of a 
rare but serious outcome following sterilization in over 70,000 women from a national, 
population-based sample over an eight-year period. We found a small but not clinically or 
statistically significant increase in the incidence of pelvic pain requiring opioid-management 
during the 12 months after hysteroscopic versus laparoscopic sterilization. Given that 
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hysteroscopic sterilization represented 50% of sterilizations in 2012 and is likely to increase 
in use, further research is needed to address concerns about adverse events.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key-points
1. This is believed to be the largest study to date evaluating adverse events after 
hysteroscopic sterilization.
2. This study provides an active comparison of hysteroscopic and laparoscopic 
sterilization, which are uncommon in the adverse events literature.
3. We used two propensity score methods to reduce bias in effect estimates 
obtained using administrative claims data.
4. We did not find compelling evidence of a clinically important increase in 
incidence of pelvic pain requiring opioid-management during the 12 months 
after hysteroscopic versus laparoscopic sterilization.
5. Findings do not raise concern for increased risk of opioid-managed pelvic pain 
in hysteroscopic sterilization patients, though effects observed in some 
sensitivity analysis (ranging from HR=0.65 to 1.53) may merit further 
investigation.
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Figure 1. 
Study exclusions.
* Patients were excluded if they had two sterilizations on the same index sterilization date. 
Patients were also excluded if they had a sterilization in their six-month history which did 
not qualify as an index sterilization due to a lack of six-month continuous enrollment before 
the service date. In the case that a woman had a second sterilization in follow-up, only the 
first sterilization was counted as an index sterilization in the analysis.
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Figure 2. 
12-month cumulative incidence of opioid-managed pelvic pain with 95% Hall-Wellner 
confidence bands and number of women at risk in A) the crude cohort and B) the propensity 
score matched cohort.
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Figure 3. 
Forest plot of hazard ratio estimates from sensitivity analyses.
SA 1: outcome definition requiring two pelvic-pain diagnoses (no prescription requirement), 
SA 2: outcome definition requiring two opioid prescription fills (no diagnosis requirement), 
SA 3: two instances of a pelvic pain diagnosis occurring within a week before an opioid 
prescription fill, SA 4: outcome definition requiring two pelvic pain diagnoses and a 
cumulative 30 days supply of opioids, SA 5: outcome definition requiring one pelvic-pain 
diagnosis and a cumulative 30 days supply of opioids, SA 6: outcome definition requiring 
one inpatient or ED pelvic pain diagnosis, SA 7: outcome definition requiring one inpatient 
or ED pelvic pain diagnosis and two opioid fills, SA 8: outcome definition including only 
625.3 (dysmenorrhea) and 789.0x (abdominal pain), SA 9: perioperative period for 
procedure-related opioids from -14 to +7 days, SA 10: perioperative period for procedure-
related opioids from -14 to 0 days, SA 11: no perioperative period for procedure-related pain 
diagnoses, SA 12: perioperative period for procedure-related opioids from 0 to +14 days, SA 
13: included a term for region-of-service in propensity score models, SA 14: require 12 
months of continuous enrollment before index sterilization date, instead of six, SA 15: allow 
up to five years of available look-back prior to sterilization (6 months continuous still 
required), SA 16: restrict cohort to years when only Essure was on the Market (2005-2008), 
Conover et al. Page 14
Pharmacoepidemiol Drug Saf. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
SA 17: allow up to five years of look-back and use outcome requiring 30 days supply of 
opioids and two pelvic pain diagnoses (combines SA 4 and SA 15).
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